LOC390031 Inhibitors
LOC390031 inhibitors target various signaling pathways and molecular mechanisms to achieve inhibition of LOC390031. LY294002 and Wortmannin are both inhibitors of PI3K, leading to a decrease in AKT phosphorylation. Since PI3K/AKT is a common signaling pathway implicated in the regulation of a multitude of proteins, LOC390031 inhibition could be achieved if its activity is contingent upon AKT signaling. U0126 and PD98059, as MEK inhibitors, prevent the downstream activation of ERK. This inhibition is significant as the MAPK/ERK pathway is integral to many cellular processes, including growth, division, and differentiation. If LOC390031 is regulated through this pathway, its activity would be diminished as a result of MEK inhibition.
In addition to these, Rapamycin and PP2 specifically target mTOR and Src family kinases, respectively. Rapamycin's inhibition of mTORC1 could hinder LOC390031 if its activity is connected to mTOR signaling pathways. mTOR is a central regulator of cell growth and metabolism, and its inhibition by rapamycin could suppress downstream effects on proteins like LOC390031, especially if they are part of the mTORC1 signaling cascade. This could affect various cellular processes such as protein synthesis and autophagy, both of which could impact the stability and function of LOC390031.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that targets Src family kinases. LOC390031 functions can be tied to tyrosine phosphorylation signaling events. Inhibition of Src kinases by dasatinib can therefore lead to reduced tyrosine phosphorylation, which may be critical for LOC390031's activity. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine is an AKT inhibitor that prevents AKT phosphorylation and activation. If LOC390031's activity is upregulated by AKT signaling, inhibition by triciribine can diminish AKT-mediated phosphorylation events that activate LOC390031. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor with specificity for RAF kinases. Since LOC390031 may be involved in the RAF/MEK/ERK pathway, sorafenib can inhibit the pathway at the RAF level, potentially reducing the phosphorylation and activity of LOC390031. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a CDK4/6 inhibitor. If LOC390031 is regulated by the cell cycle, its activity could be tied to CDK4/6-mediated phosphorylation events. Inhibition by palbociclib can disrupt this regulation, leading to decreased activity of LOC390031. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor. By inhibiting multiple receptor tyrosine kinases that may activate signaling cascades involving LOC390031, sunitinib can indirectly inhibit LOC390031 activity by preventing upstream kinase signaling. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an EGFR inhibitor. If LOC390031 is activated downstream of EGFR signaling, inhibition of EGFR by erlotinib can lead to a reduction in the phosphorylation and activation of LOC390031. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a BCR-ABL tyrosine kinase inhibitor. It can inhibit the ABL kinase which may be necessary for the phosphorylation and activation of LOC390031, leading to its functional inhibition. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib inhibits both EGFR and HER2 kinases. Should LOC390031 be involved in signaling pathways downstream of these receptors, lapatinib can inhibit the initiation of these pathways, resulting in decreased LOC390031 activity. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib is a VEGFR, EGFR, and RET inhibitor. By inhibiting these kinases, vandetanib can disrupt signaling pathways critical for LOC390031 activity, leading to its functional inhibition. | ||||||